Clinical Trial Update: Durvalumab in DLBCL After Autologous Transplant [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating durvalumab for diffuse large B-cell lymphoma after autologous transplant has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: Lymphoma, Large B-Cell, Diffuse | Phase 2 | Status: WITHDRAWN